Söndag 11 Maj | 22:27:41 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2026-02-19 08:00 Bokslutskommuniké 2025
2025-10-31 08:00 Kvartalsrapport 2025-Q3
2025-08-14 08:00 Kvartalsrapport 2025-Q2
2025-05-16 N/A X-dag ordinarie utdelning IMP A 0.00 SEK
2025-05-15 N/A Årsstämma
2025-05-09 - Kvartalsrapport 2025-Q1
2025-02-14 - Bokslutskommuniké 2024
2024-11-15 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag ordinarie utdelning IMP A 0.00 SEK
2024-05-22 - Årsstämma
2024-05-15 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2023-11-22 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning IMP A 0.00 SEK
2023-05-25 - Årsstämma
2023-05-12 - Kvartalsrapport 2023-Q1
2023-02-17 - Bokslutskommuniké 2022
2022-11-15 - Kvartalsrapport 2022-Q3
2022-08-23 - Kvartalsrapport 2022-Q2
2022-05-11 - X-dag ordinarie utdelning IMP A 0.00 SEK
2022-05-11 - Kvartalsrapport 2022-Q1
2022-05-10 - Årsstämma
2022-02-18 - Bokslutskommuniké 2021
2021-11-24 - Kvartalsrapport 2021-Q3
2021-09-17 - Extra Bolagsstämma 2021
2021-08-24 - Kvartalsrapport 2021-Q2
2021-05-12 - Kvartalsrapport 2021-Q1
2021-04-19 - X-dag ordinarie utdelning IMP A 0.00 SEK
2021-04-16 - Årsstämma
2021-02-25 - Bokslutskommuniké 2020
2020-11-18 - Kvartalsrapport 2020-Q3

Beskrivning

LandLiechtenstein
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Implantica är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar implanterbara medicinska instrument, som vidare används för behandling av sjukdomar som berör matstrupen. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster, särskilt inriktat mot eHälsa. Verksamheten drivs globalt med störst närvaro inom Nordamerika samt Europa.
2023-08-21 08:00:00

Implantica AG (publ) will arrange a Capital Markets Day (CMD) for investors, analysts and media on Tuesday, 26 September 2023, starting at 14:00 CEST. The event will be held at Västra Trädgårdsgatan 19 in Stockholm and can be followed as a live webcast for those not attending in person. The webcast will be available on-demand after the event on our website.

The focus of the day is Implantica's efforts to bring RefluxStop to the market. CEO Peter Forsell, other members of the board and management team, and key opinion leader surgeons in anti-reflux surgery will be present.

More information will be made available at a later stage.

For further information, please contact:

Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, info@fnca.se

The information was sent for publication, through the agency of the contact person set out above, on August 21, 2023, at 8:00 a.m. CEST.

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

Newsroom
https://www.implantica.com/media/media-kit

Community

https://www.linkedin.com/implantica

https://www.twitter.com/implantica